| 标题 |
Atorvastatin safety and pharmacokinetics in acute kawasaki disease patients with coronary artery abnormalities
阿托伐他汀在急性川崎病冠状动脉异常患者中的安全性和药代动力学
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | Introduction: Despite therapy with intravenous immunoglobulin, 25% of children with Kawasaki disease (KD) develop coronary artery abnormalities (CAA) and endothelial cell (EC) dysfunction. Based on the pleiotropic effects of statins on restoring EC homeostasis, we performed a Phase I clinical trial of atorvastatin for acute KD patients with early CAA. Hypothesis: A sixweek (wk) course of atorvastatin in acute KD patients (pts) with CAA will be safe, welltolerated and restore EC homeostasis. Methods: This twocenter, Phase I, open label, dose escalation trial enrolled acute KD subjects aged 217 years with an initial CA Z score ≥ 2.5 in a 6wk study of atorvastatin (0.125, 0.25, 0.5 and 0.75 mg/kg/day). Demographic, clinical and laboratory data, and echo core lab readings were collected at baseline, |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
浮游
研究生end
Zx_1993
无敌霸王花
zcl
Criminology34
无极微光
不配.
子车茗
小青椒
镓氧锌钇铀
小杭76
wy.he
殷勤的紫槐
那时花开
wlscj
Li
sissiarno
kister
核桃
大宝S欧D蜜
Tourist
eric888
pcr163
pluto
LaTeXer
凤凰
dew
皖公网安备34019202002308
